| Species |
Human |
| Protein Construction |
| Avi |
His |
NKG2C&CD94 [Glu98-Leu231 (NKG2C) & Ser34-Ile179 (CD94)]
Accession # P26717 (NKG2C) & Q13241-1 (CD94) |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
15.3kDa (NKG2C)&17.9kDa (CD94) |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 25-35 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
NKG2C&CD94 is a C-type lectin heterodimer on NK cells and CD8+ cytotoxic T-cells, it can recognize peptides derived from the intracellular proteins in the context of HLA-E. NKG2C&CD94 itself has no signal transduction function but is an activating receptor on the surface of NK cells that involved in driving the NK-cell expansion. |
| Synonyms |
NKG2C&CD94; NKG2C; CD94 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
